38 completed, 6 unknown, 4 terminated, 3 withdrawn. 54 Phase 2, 6 Phase 1, 5 Phase 3.
Follow Candidiasis: new trials by email Literature Review of Candidiasis trials Research Report on Candidiasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence OCF001 Intravaginal Gel, Placebo Gel - Candidiasis, Vulvovaginal | Phase 2 | Recruiting | Sano Chemicals Inc | 36 | 2026-06-04 | 2026-06-15 |
| CelAgace™ OraRinse Solution for Treatment of Candidiasis silver citrate complex and acemannan - Candidiasis, Oral | Phase 1 / Phase 2 | Unknown | CelaCare Technologies, Inc. | 15 | 2024-09-01 | 2024-02-09 |
| Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | NEXBIOME THERAPEUTICS | 165 | 2024-07-08 | 2024-06-12 |
| Postbiotic as Adjunct Treatment for Vaginal Candidiasis Postbiotic, Placebo - Vaginal Candidiasis | Phase 2 / Phase 3 | Completed | Min-Tze LIONG | 99 | 2024-06-02 | 2026-07-07 |
| Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis Clotrimazole+Lactulose., Canesten (Clotrimazole), Lactulose - Candidal Vulvovaginitis (ICD-10 Code: B37.3), Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Recruiting | AVVA Pharmaceuticals Ltd. | 264 | 2024-02-29 | 2025-02-19 |
| Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study Vaccine - Recurrent Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Active not recruiting | LimmaTech Biologics AG | 251 | 2023-12-06 | 2026-03-04 |
| Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis. Venus 20 + 0,064, Venus 20 + 1, Venus 20 + 4 - Vulvovaginal Candidiasis | Phase 2 | Withdrawn | EMS | 2022-07-01 | 2022-08-10 | |
| A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis Chlorhexidine Gluconate, Fluconazole - Candidiasis, Vulvovaginal | Phase 2 | Unknown | Karolinska Institutet | 60 | 2022-04-27 | 2022-05-20 |
| Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia Interferon Gamma-1B - Candidemia | Phase 2 | Completed | Radboud University Medical Center | 65 | 2022-03-31 | 2026-06-22 |
| Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and Invasive Aspergillosis Amphotericin B cholesteryl sulfate complex for injection(ABCD) - Invasive Candidiasis, Invasive Aspergillosis | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 60 | 2020-01-01 | 2020-01-13 |
| An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris APX001 - Candidemia, Invasive Candidiases | Phase 2 | Completed | Basilea Pharmaceutica | 9 | 2019-12-13 | 2025-09-16 |
| Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Oral Encochleated Amphotericin B (CAMB) - Vulvovaginal Candidiases, Yeast Infection | Phase 2 | Withdrawn | Matinas BioPharma Nanotechnologies, Inc. | 2019-12-01 | 2019-03-08 | |
| A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC) Prof-001, Fluconazole 150 mg, Placebo cream - Recurrent Vulvovaginal Candidiasis | Phase 2 / Phase 3 | Unknown | ProFem GmbH | 432 | 2019-10-01 | 2022-09-22 |
| An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia APX001 - Candidemia | Phase 2 | Completed | Basilea Pharmaceutica | 21 | 2018-10-03 | 2025-09-16 |
| Patients With Vulvovaginal Candidiasis EPP-AF Gel 1%, EPP-AF Gel 2%, Clotrimazole - Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | University of Sao Paulo | 90 | 2018-01-30 | 2018-10-19 |
| Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Fluconazole, SCY-078 - Candida Vulvovaginitis | Phase 2 | Completed | Scynexis, Inc. | 186 | 2017-08-01 | 2021-08-12 |
| ProF-001_Phase IIa Candiplus, Clotrimazole - Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Completed | ProFem GmbH | 84 | 2017-04-04 | 2019-03-14 |
| Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Oral Encochleated Amphotericin B (CAMB), Fluconazole - Vulvovaginitis, Yeast Infection | Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 137 | 2016-11-01 | 2018-11-02 |
| CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Amphotericin B - Candidiasis, Chronic Mucocutaneous | Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 4 | 2016-09-27 | 2024-08-07 |
| CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension CD101, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 207 | 2016-07-26 | 2020-12-08 |
Showing 20 of 54. Sign in to see all of them.
Candidiasis, Vulvovaginal (23) · Candidiasis, Invasive (10) · Candidemia (9) · Candidiasis, Oral (7) · Mycoses (5) · Aspergillosis (3) · HIV Infections (3) · Stomatitis, Denture (3) · Torulopsis (3) · Vaginitis (3) · Vaginosis, Bacterial (3) · Vulvovaginitis (3) · AIDS-Related Opportunistic Infections (2) · Invasive Fungal Infections (2)
Bacterial Infections and Mycoses (54) · Infections (54) · Mycoses (49) · Genital Diseases (26) · Urogenital Diseases (26) · Female Urogenital Diseases (23) · Female Urogenital Diseases and Pregnancy Complications (23) · Genital Diseases, Female (23) · Vulvar Diseases (23) · Vulvitis (23) · Vaginal Diseases (22) · Vaginitis (20) · Vulvovaginitis (20) · Invasive Fungal Infections (14)
Fluconazole (11) · Caspofungin (8) · Micafungin (4) · Amphotericin B (3) · Anidulafungin (3) · Clotrimazole (3) · ibrexafungerp (3) · VT-1161 (2) · Antifungal Agents (1) · Injections (1) · Lactulose (1) · Miconazole (1) · Saline Solution (1) · TOL-463 (1) · Vaccines (1)
Merck Sharp & Dohme LLC (8) · Matinas BioPharma Nanotechnologies, Inc. (3) · Pfizer (3) · Scynexis, Inc. (3) · Basilea Pharmaceutica (2) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Kerman University of Medical Sciences (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · ProFem GmbH (2) · Viamet (2) · AM-Pharma (1) · AVVA Pharmaceuticals Ltd. (1) · Almirall, S.A. (1) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Inc (1)
United States (24) · Germany (6) · Spain (6) · Belgium (5) · Austria (4) · Italy (4) · France (3) · Israel (3) · Netherlands (3) · Poland (3) · Canada (2) · Dominican Republic (2) · Greece (2) · Guatemala (2) · Honduras (2)
David Angulo, MD (3) · Marc Engelhardt (2) · Alena Jandourek, MD (1) · Alexandra Freeman, MD (1) · Cathrin Alvendal, MD, PhD (1) · Christina Muzny, MD (1) · Christoph Willers, MD, MBA (1) · Douglas Kling (1) · Gregory Reid, MSc, MBA (1) · Herbert Kiss, Ao.Univ.Prof.Dr. (1) · Herbert Kiss, Prof. (1) · Jacqueline M. Plemons, DDS, MS (1)
PMID 36396498, PMID 16436724, PMID 25701307, PMID 29304768, PMID 29534874, PMID 29697768, PMID 29744900, PMID 30184181, PMID 31586424, PMID 32818963, PMID 32955088, PMID 33558294, PMID 34555149, PMID 35699443, PMID 37022196, PMID 37596890, PMID 38008099, PMID 38502709, PMID 39468640, PMID 39529079, PMID 40970688, PMID 41845293, PMID 41940006
2009 (3), 2014 (1), 2015 (1), 2023 (1)